Afatinib as a Potential Therapeutic Option for Patients With NSCLC With EGFR G724S

EGFR G724S has been described to mediate resistance to first- and third-generation EGFR tyrosine kinase inhibitors (TKIs). In vitro experiments have provided compelling evidence that G724S retains sensitivity for afatinib. Nevertheless, limited data have reported the clinical efficacy of afatinib in patients with NSCLC harboring G724S mutation.We identified 52 patients with NSCLC with EGFR G724S from an inhouse database and comprehensively...